These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 31913695)
41. The emerging role of CXC chemokines in epithelial ovarian cancer. Rainczuk A; Rao J; Gathercole J; Stephens AN Reproduction; 2012 Sep; 144(3):303-17. PubMed ID: 22771929 [TBL] [Abstract][Full Text] [Related]
42. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. Belperio JA; Keane MP; Burdick MD; Lynch JP; Zisman DA; Xue YY; Li K; Ardehali A; Ross DJ; Strieter RM J Immunol; 2003 Nov; 171(9):4844-52. PubMed ID: 14568964 [TBL] [Abstract][Full Text] [Related]
43. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum. Müller M; Carter S; Hofer MJ; Campbell IL Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305 [TBL] [Abstract][Full Text] [Related]
44. Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis. Furuya M; Yoneyama T; Miyagi E; Tanaka R; Nagahama K; Miyagi Y; Nagashima Y; Hirahara F; Inayama Y; Aoki I Gynecol Oncol; 2011 Sep; 122(3):648-55. PubMed ID: 21684584 [TBL] [Abstract][Full Text] [Related]
45. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Eck M; Schmausser B; Scheller K; Brändlein S; Müller-Hermelink HK Clin Exp Immunol; 2003 Dec; 134(3):508-15. PubMed ID: 14632759 [TBL] [Abstract][Full Text] [Related]
46. CXCR3 as a molecular target in breast cancer metastasis: inhibition of tumor cell migration and promotion of host anti-tumor immunity. Zhu G; Yan HH; Pang Y; Jian J; Achyut BR; Liang X; Weiss JM; Wiltrout RH; Hollander MC; Yang L Oncotarget; 2015 Dec; 6(41):43408-19. PubMed ID: 26485767 [TBL] [Abstract][Full Text] [Related]
47. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901 [TBL] [Abstract][Full Text] [Related]
48. The Inflammatory CXC Chemokines, GROα Cao Y; Huang H; Wang Z; Zhang G Immunol Invest; 2017 May; 46(4):361-374. PubMed ID: 28375674 [TBL] [Abstract][Full Text] [Related]
49. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Xanthou G; Duchesnes CE; Williams TJ; Pease JE Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299 [TBL] [Abstract][Full Text] [Related]
50. The role of CXC chemokines and their receptors in cancer. Vandercappellen J; Van Damme J; Struyf S Cancer Lett; 2008 Aug; 267(2):226-44. PubMed ID: 18579287 [TBL] [Abstract][Full Text] [Related]
51. The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment. Susek KH; Karvouni M; Alici E; Lundqvist A Front Immunol; 2018; 9():2159. PubMed ID: 30319622 [TBL] [Abstract][Full Text] [Related]
52. The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Arenberg DA; Zlotnick A; Strom SR; Burdick MD; Strieter RM Cancer Immunol Immunother; 2001 Jan; 49(11):587-92. PubMed ID: 11225989 [TBL] [Abstract][Full Text] [Related]
53. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685 [TBL] [Abstract][Full Text] [Related]
55. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design. Trotta T; Costantini S; Colonna G Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124 [TBL] [Abstract][Full Text] [Related]
56. Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells. Ohshima K; Tutiya T; Yamaguchi T; Suzuki K; Suzumiya J; Kawasaki C; Haraoka S; Kikuchi M Int J Cancer; 2002 Apr; 98(4):567-72. PubMed ID: 11920617 [TBL] [Abstract][Full Text] [Related]
57. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826 [TBL] [Abstract][Full Text] [Related]
58. Analysis of cysteine-X-cysteine motif chemokine ligands 9, 10, and 11, their receptor CXCR3, and their possible role on the recruitment of immune cells at the maternal-conceptus interface in pigs. Han J; Gu MJ; Yoo I; Choi Y; Jang H; Kim M; Yun CH; Ka H Biol Reprod; 2017 Jul; 97(1):69-80. PubMed ID: 28859287 [TBL] [Abstract][Full Text] [Related]
59. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856 [TBL] [Abstract][Full Text] [Related]
60. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection. Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]